文献速递消化系统肿瘤

原发肿瘤位置对转移性结直肠癌预后和治疗结局的影响:两项一线帕尼单抗随机研究结果

Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
PubMed 文献 · Ann Oncol · 2017-01-01

两项帕尼单抗一线治疗转移性结直肠癌随机研究(PRIME和PEAK)的回顾性分析显示,在RAS野生型患者中,右侧原发肿瘤患者所有疗效参数均劣于左侧肿瘤患者。左侧肿瘤患者中,含帕尼单抗方案较对照方案改善结局,包括总生存优势。右侧肿瘤患者因例数较少无法得出最佳治疗结论。

要点

  • RAS野生型患者中,右侧原发肿瘤患者所有疗效参数均劣于左侧肿瘤患者。
  • 左侧肿瘤患者中,含帕尼单抗方案较对照方案改善结局,包括总生存优势。
  • 右侧肿瘤患者因例数较少无法就最佳治疗得出最终结论。

核心结论

  • 在RAS野生型患者中,右侧原发肿瘤较左侧肿瘤预后更差,与一线接受的治疗无关。
  • RAS野生型左侧肿瘤患者从含帕尼单抗治疗中获益大于单纯化疗或化疗联合贝伐珠单抗,包括总生存优势(治疗差异:PRIME 6.7个月;PEAK 11.4个月)。
  • RAS野生型右侧转移性结直肠癌患者因例数相对较少,无法就最佳治疗得出最终结论。
  • 原文结论指出该领域需进一步研究。

研究设计与样本

  • 对两项帕尼单抗一线治疗随机研究(PRIME和PEAK)的回顾性分析,针对RAS野生型患者按原发肿瘤位置分析治疗结局。
  • PRIME(3期;NCT00364013)比较帕尼单抗联合FOLFOX与单纯FOLFOX。
  • PEAK(2期;NCT00819780)比较帕尼单抗联合FOLFOX与贝伐珠单抗联合FOLFOX。
  • 盲肠至横结肠的肿瘤编码为右侧,脾曲至直肠的肿瘤视为左侧。

主要发现

  • RAS野生型人群中肿瘤位置确定率为83%(n=559/675);78%患者(n=435)为左侧肿瘤,22%(n=124)为右侧肿瘤。
  • 在RAS野生型人群及RAS/BRAF野生型亚组中,右侧肿瘤患者所有疗效参数均劣于左侧肿瘤患者。
  • 左侧肿瘤患者中,帕尼单抗较对照治疗提供更好结局,包括中位总生存:PRIME 30.3个月 vs 23.6个月,校正风险比=0.73,P=0.0112;PEAK 43.4个月 vs 32.0个月,校正风险比=0.77,P=0.3125。

局限性

  • 原文为回顾性分析。
  • RAS野生型右侧转移性结直肠癌患者例数相对较少,无法就最佳治疗得出最终结论。
  • 原文结论指出该领域需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. MATERIALS AND METHODS: Data from two randomized first-line panitumumab trials were analyzed for treatment outcomes by primary tumor sidedness for RAS WT patients. PRIME (phase 3; NCT00364013) compared panitumumab plus FOLFOX versus FOLFOX alone; PEAK (phase 2; NCT00819780) compared panitumumab plus FOLFOX versus bevacizumab plus FOLFOX. Primary tumors located in the cecum to transverse colon were coded as right-sided, while tumors located from the splenic flexure to rectum were considered left-sided. RESULTS: Tumor sidedness ascertainment (RAS WT population) was 83% (n = 559/675); 78% of patients (n = 435) had left-sided and 22% (n = 124) had right-sided tumors. Patients with right-sided tumors did worse for all efficacy parameters compared with patients with left-sided disease in the RAS WT population and also in the RAS/BRAF WT subgroup. In patients with left-sided tumors, panitumumab provided better outcomes than the comparator treatment, including on median overall survival (PRIME: 30.3 versus 23.6 months, adjusted hazard ratio = 0.73, P = 0.0112; PEAK: 43.4 versus 32.0 months, adjusted hazard ratio = 0.77, P = 0.3125). CONCLUSION: The results of these retrospective analyses confirm that in RAS WT patients, right-sided primary tumors are associated with worse prognosis than left-sided tumors, regardless of first-line treatment received. RAS WT patients with left-sided tumors derive greater benefit from panitumumab-containing treatment than chemotherapy alone or combined with bevacizumab, including an overall survival advantage (treatment difference: PRIME 6.7 months; PEAK 11.4 months). No final conclusions regarding optimal treatment could be drawn for RAS WT patients with right-sided mCRC due to the relatively low number of paxtients. Further research in this field is warranted. TRIAL REGISTRATION (CLINICALTRIALS.GOV): PRIME (NCT00364013), PEAK (NCT00819780).

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Boeckx N, Koukakis R, Op de Beeck K, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017. PMID: 28449055. doi:10.1093/annonc/mdx119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。